Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 1,620,000 shares, a growth of 51.4% from the July 31st total of 1,070,000 shares. Based on an average daily trading volume, of 559,700 shares, the short-interest ratio is presently 2.9 days.
Wall Street Analyst Weigh In
BCLI has been the topic of several analyst reports. StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a report on Thursday, August 22nd. They issued a “hold” rating on the stock. Maxim Group upgraded Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Thursday, July 11th.
Check Out Our Latest Stock Report on BCLI
Brainstorm Cell Therapeutics Stock Performance
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). During the same quarter in the previous year, the firm earned ($0.27) earnings per share. Equities analysts anticipate that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors own 14.33% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.